Mexico: Devaluation hits health Pledges

23 January 1995

In Mexico, the pledge of new President Ernesto Zedillo Ponce de Leon to undertake a major restructuring of the health care sector as a priority has been dealt a very significant blow by the sharp devaluation of the peso.

Observers expect, at best, serious delays in the implementation of the ambitious projects announced by the president when he was inaugurated on December 1, 1994, for a six-year term. He has called for a 60-day moratorium on price rises, but these have continued to move up despite fines and temporary business closures. Cuts in government spending and the freeze on salaries will inevitably affect drug prices; even before devaluation, they rose 50%-100% in 1994. Moreover, with a large share of drugs on the market containing ingredients from overseas, further sharp price rises are expected in the near future.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight